BuSpar Tapering Guide
buspirone
Overview
Buspirone is an azapirone anxiolytic approved for generalized anxiety disorder (GAD). Unlike benzodiazepines, it has no sedative, muscle-relaxant, or anticonvulsant properties and is not associated with dependence.
5mg, 7.5mg, 10mg, 15mg, 30mg (typically dosed BID-TID)
Tablets: 5mg, 7.5mg, 10mg, 15mg, 30mg (most are scored for splitting)
Category B (animal studies show no risk; human data limited)
Mechanism of Action
Partial agonist at presynaptic and postsynaptic 5-HT1A serotonin receptors. Weak dopamine D2 antagonist. Onset of anxiolytic effect is delayed (2-4 weeks).
Taper Notes
Buspirone has minimal classical withdrawal because it does not act on GABA. Most patients can discontinue with a 1-2 week stepdown. Rebound anxiety is the main concern.
Hyperbolic Tapering Guidance
Buspirone is not associated with the dependence or discontinuation syndrome seen with SSRIs or benzodiazepines. A short stepdown (e.g., halve dose for 1 week, then stop) is usually sufficient. Slower if used long-term or in combination with other anxiolytics.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Tapering Protocol
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Initial reduction | 1 week | Halve total daily dose. Most patients tolerate this step well. |
| Final reduction | 1 week | Reduce to lowest available dose, then stop. Watch for rebound anxiety. |
Withdrawal Timeline
1-3 days after stopping
3-7 days
Typically within 1-2 weeks
Rebound anxiety may persist 2-4 weeks if the underlying anxiety condition is not addressed
Community Tips
Practical insights shared by members tapering BuSpar. Not medical advice — always consult your prescriber.
- 1Buspirone is one of the easier psychiatric medications to come off — most members do not experience the kind of withdrawal SSRIs or benzos cause.
- 2Avoid grapefruit juice during your taper — it can spike levels and add unnecessary side effects.
- 3If your anxiety returns within 1-2 weeks of stopping, that is more likely the underlying condition re-emerging rather than withdrawal.
- 4Plan a non-pharmacological anxiety toolkit (CBT skills, exercise, sleep) before stopping — it pays off in the rebound period.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- MAOIs — contraindicated (hypertensive crisis risk)
- Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) — markedly increased exposure
- Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) — markedly reduced exposure
Food Interactions
- Grapefruit juice substantially increases plasma levels via CYP3A4 inhibition — avoid
- Take consistently with or without food to avoid dose-curve fluctuations
Contraindications
- Concurrent or recent (within 14 days) MAOI use
- Severe hepatic or renal impairment
- Known hypersensitivity to buspirone
Toxicity
Generally low toxicity. Serotonin syndrome possible with serotonergic combinations. Dizziness, headache, nausea, and lightheadedness most common adverse effects.
Pharmacokinetics
ADME Profile
Rapidly absorbed but extensive first-pass metabolism limits oral bioavailability to ~4%. Food increases bioavailability.
~5.3 L/kg
Extensive hepatic metabolism via CYP3A4 to multiple metabolites including the active 1-(2-pyrimidinyl)-piperazine (1-PP).
Renal (~29-63% as metabolites), fecal (~18-38%).
~95%
~28 mL/min/kg
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Sources & References
BuSpar (buspirone) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Deprescribing.org — Evidence-based deprescribing algorithms from the Bruyère Research Institute
- Royal College of Psychiatrists — Stopping antidepressants — UK clinical guidance on safely discontinuing antidepressants
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — tapering forum — Long-running community archive of antidepressant taper experiences
- Inner Compass Initiative — Withdrawal Project — Peer-led resources for psychiatric drug withdrawal
- Mad in America — antidepressant withdrawal archive — Journalism and personal narratives on SSRI/SNRI discontinuation
- RxISK — adverse drug reaction reporting — Independent database of patient-reported adverse effects
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.